Future directions in antithrombotic therapy: emphasis on venous thromboembolism.
Axelrod
D A
DA
Department of Surgery, Robert Wood Johnson Clinical Scholars Program, University of Michigan, Ann Arbor, USA.
Wakefield
T W
TW
D000721:Ancrod / Q000494:pharmacology / Q000627:therapeutic use; D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use; D000991:Antithrombins / Q000494:pharmacology / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D005544:Forecasting; D006493:Heparin / Q000494:pharmacology / Q000627:therapeutic use; D024764:Hirudin Therapy; D006629:Hirudins / Q000494:pharmacology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D013923:Thromboembolism / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000379:methods / Q000639:trends*; D020246:Venous Thrombosis / Q000188:drug therapy*
D000925:Anticoagulants; D000991:Antithrombins; D005343:Fibrinolytic Agents; D006629:Hirudins; D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D000721:Ancrod